Thanks for the info. I made an error with the date (November 2023), however, my information as per Leslie's comments in the NWR Virtual Healthcare Conference last week remains accurate.
I have pulled this excerpt from Imugene's PHASE 1 CF33-HNIS STUDY UPDATE from May 2024.
I've re-listened to Leslie's comments from the presentation which are "...we have certainly dosed more than 40 at this point...but at the time of our data cut we looked at 40 patients".
You can listen from the 9:12 mark.
I believe the data update will see a significant increase in patients dosed for a number of reasons.
1. Early Vaxinia results are informing the direction of expansion trials based on efficacy, unmet need and a clear pathway to regulatory approval. 2. The basket trial design is intentionally open to all solid tumours to see where Vaxinia is having best results. 3. We are still establishing Optimal Biological Dose. 4. Delays in Vaxinia results may also be due to strict patient inclusion criteria and the longer we wait, the more durability data we gather.
I am excited for the data updates to arrive and will certainly look forward to reading the thoughts / extrapolations of knowledgeable & esteemed posters.
My opinions, interpretations and thoughts. DYOR, GLTAH, chur.
Shornbra
IMU Price at posting:
3.2¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)